Who are Vitamin D: solid form, start weekly's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vitamin D: liquid form, start weekly, Vitamin D: liquid form, start monthly, Vitamin D: solid form, start monthly, Vitamin D (Cholecalciferol ), Vit D, Vitamin D 3.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vitamin-d-solid-form-start-weekly.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Vitamin D: solid form, start weekly — Competitive Intelligence Brief

Vitamin D: solid form, start weekly (Vitamin D: solid form, start weekly) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin/Steroid hormone. Area: Endocrinology, Bone Health, Immunology.

marketed Vitamin/Steroid hormone Vitamin D receptor (VDR) Endocrinology, Bone Health, Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Vitamin D: solid form, start weekly (Vitamin D: solid form, start weekly) — University Hospital, Basel, Switzerland. Vitamin D acts as a steroid hormone precursor that regulates calcium and phosphate homeostasis, immune function, and cellular differentiation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Vitamin D: solid form, start weekly TARGET	Vitamin D: solid form, start weekly	University Hospital, Basel, Switzerland	marketed	Vitamin/Steroid hormone	Vitamin D receptor (VDR)
Vitamin D: liquid form, start weekly	Vitamin D: liquid form, start weekly	University Hospital, Basel, Switzerland	marketed	Vitamin/steroid hormone	Vitamin D receptor (VDR)
Vitamin D: liquid form, start monthly	Vitamin D: liquid form, start monthly	University Hospital, Basel, Switzerland	marketed	Vitamin/steroid hormone	Vitamin D receptor (VDR)
Vitamin D: solid form, start monthly	Vitamin D: solid form, start monthly	University Hospital, Basel, Switzerland	marketed	Vitamin/steroid hormone	Vitamin D receptor (VDR)
Vitamin D (Cholecalciferol )	Vitamin D (Cholecalciferol )	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Vitamin/Steroid hormone	Vitamin D receptor (VDR)
Vit D	Vit D	Al-Balqa Applied University	marketed	Vitamin/Steroid hormone	Vitamin D receptor (VDR)
Vitamin D 3	Vitamin D 3	Second Affiliated Hospital of Wenzhou Medical University	marketed	Vitamin/Steroid hormone	Vitamin D receptor (VDR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin/Steroid hormone class)

Al-Balqa Applied University · 1 drug in this class
Brigham and Women's Hospital · 1 drug in this class
McGill University Health Centre/Research Institute of the McGill University Health Centre · 1 drug in this class
Second Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
University Hospital, Basel, Switzerland · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vitamin D: solid form, start weekly — Competitive Intelligence Brief. https://druglandscape.com/ci/vitamin-d-solid-form-start-weekly. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab